






































Pretreatment integrase strand transfer inhibitor
resistance in North Carolina from 2010–2016
Timothy W. Menzaa, Rachael Billockb, Erika Samoffc,
Joseph J. Erona and Ann M. Dennisa
Objective: We sought to define the prevalence of pretreatment integrase strand transfer 
inhibitor (INSTI) resistance and assess the transmission networks of those with pretreat-
ment INSTI resistance.
Design: A retrospective cohort study of HIV-positive patients with genotypic resistance 
testing sent to a single referral laboratory in North Carolina between 2010 and 2016.
Methods: We linked genotype and public health data for in-care HIV-positive individ-
uals to determine the prevalence of INSTI resistance among treatment-naive (defined as 
those with a first genotype 3 months after diagnosis) and treatment-experienced 
(defined as those with a first genotype >3 months after diagnosis) patients. We 
performed molecular and phylogenetic analyses to assess whether pretreatment INSTI 
resistance mutations represented clustered HIV transmission.
Results: Of 8825 individuals who contributed sequences for protease, reverse tran-
scriptase, or INSTI genotypic resistance testing during the study period, 2784 (31%) 
contributed at least one sequence for INSTI resistance testing. Of these, 840 were 
treatment-naive individuals and 20 [2.4%, 95% confidence interval (CI): 1.5, 3.6%] had 
INSTI mutations; only two (0.2%, 95% CI: 0.02, 0.9%) had major mutations. Of 1944 
treatment-experienced individuals, 9.6% (95% CI: 8.3, 11.0%) had any INSTI mutation 
and 7.0% (95% CI: 5.9, 8.3%) had major mutations; the prevalence of INSTI mutations 
among treatment-experienced patients decreased overtime (P < 0.001). In total 12 of 20 
individuals with pretreatment INSTI mutations were part of 10 molecular transmission 
clusters; only one cluster shared identical minor mutations.
Conclusion: The prevalence of major pretreatment INSTI resistance is very low. 
Pretreatment INSTI mutations do not appear to represent clustered HIV transmission. 
AIDS 2017, 31:2235–2244
Keywords: cluster analysis, HIV, integrase strand transfer inhibitors, 
phylogenetic analysis, transmitted drug resistance
Introduction
Integrase strand transfer inhibitors (INSTIs) are part of
recommended first-line regimens for the treatment
of HIV infection [1]. As observed with other classes of
antiretroviral medications, increasing use of INSTIs and
treatment failures on INSTIs may subsequently lead to an
increase in pretreatment INSTI resistance [2,3]. Although
there are two case reports of antiretroviral-naive
individuals with major INSTI mutations in the context
of multiclass antiretroviral drug resistance [4,5], to date,
major INSTI mutations are rare among cohorts of
treatment-naive individuals in Europe [6–10], the
Middle East [11], and the United States [12].
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There are currently no data on pretreatment INSTI
resistance among HIV-positive individuals in the South,
the epicenter of the HIV epidemic in the United States.
Currently, the United States Department of Health and
Human Services recommends routine pretreatment
reverse transcriptase and protease resistance testing but
recommends INSTI resistance testing only if transmitted
INSTI resistance is a concern (e.g. in the setting of
multiclass drug resistance) [13]. In an analysis of INSTI
resistance in the United States, 16.5% of HIV-positive
patients in the south with INSTI resistance testing
between 2009 and 2012 had a major mutation [14]. This
analysis, however, did not distinguish between treatment-
naı̈ve and treatment-experienced patients. HIV-positive
patients initiating antiretroviral therapy at the University
of North Carolina from 1996 to 2014 whose initial
regimen contained an INSTI were less likely to
discontinue therapy and less likely to experience virologic
failure compared to those whose initial regimen did not
contain an INSTI [15]. The durability of INSTI-
containing regimens likely captures their safety, tolera-
bility, and efficacy, factors that might reduce the risk of
development and subsequent transmission of resistance
compared to other regimens [16].
The present study has three main objectives. First, we
define the prevalence of INSTI resistance mutations
among treatment-naive and treatment-experienced in-
dividuals in North Carolina from 2010 to 2016. Second,
we assess the sociodemographic and clinical character-
istics of patients with INSTI resistance mutations. Finally,
we use HIV sequences to construct transmission clusters
and phylogenetic trees to investigate transmission net-
works of individuals with INSTI resistance mutations.
Methods
Study population
We analyzed HIV-1 sequences derived from samples sent to
the largest referral laboratory in North Carolina (Labora-
tory Corporation of America, Research Triangle Park,
North Carolina, USA) for genotypic resistance testing
from 16 November 2010 through 22 September 2016. We
linked sequence data to the North Carolina State Division
of Public Health’s Enhanced HIV/AIDS Reporting
System that included age, sex, race/ethnicity, transmission
risk category, CD4þ cell count and viral load at the time of
genotyping, and dates of diagnosis and genotypic resistance
testing. We included individuals who were at least 18 years
of age at resistance testing. The final dataset included 8825
individuals with 12 159 sequences for protease, reverse
transcriptase, or INSTI resistance testing during the study
period; 2784 (31%) of these individuals had 3162 sequences
for INSTI resistance testing. With the exception of the
cluster analysis described below, the 2784 individuals with
INSTI resistance testing represent the population of
interest for all analyses.
We examined diagnosis and sequence dates in Enhanced
HIV/AIDS Reporting System to define individuals as
treatment naive and treatment experienced. The Centers
for Disease Control and Prevention estimate that 80% of
HIV-positive people linked to care within 3 months of
diagnosis in 2011 [17] and that 72% of blacks and 79%
of whites with HIV infection linked to care within
1 month of diagnosis in 2014 [18]. Thus, we defined an
individual as treatment naive if their first genotypic
resistance test was sent within 3 months of diagnosis to
capture the majority of newly diagnosed individuals
linking to care for the first time. We classified individuals
as treatment experienced if their first genotypic resistance
test was sent more than 3 months after diagnosis.
The University of North Carolina Institutional Review
Board (IRB #16–2345) approved this study.
Definition of resistance mutations
Based on the 2015 International Antiviral Society Update
of the Drug Resistance Mutations in HIV-1, we defined
major INSTI mutations as: T66I, E92Q, F121Y,
Y143RHC, S147G, Q148HKR, and N155H [19]. Minor
or accessory mutations were defined as: T66AK, L74M,
E92G, T97A, E138AK, G140AS, and R263K.
Genotyping and analysis of nucleotide sequence
data
Genotypic resistance testing was performed using
GenoSure MG (Monogram Biosciences, South San
Francisco, California, USA), GenoSure Integrase (Labo-
ratory Corporation of America, Research Triangle
Park, North Carolina, USA), and GenoSure PRIme
(Monogram Biosciences). We identified INSTI, protease,
and reverse transcriptase mutations using the Stanford
University HIV Drug Resistance Database genotypic
resistance interpretation algorithm with Sierra v1.1 [20].
We confirmed HIV subtypes using the context-based
modeling for expeditious typing tool [21].
Cluster analysis
We performed a molecular cluster analysis using
HIV-TRACE, available at www.hivtrace.org [22] to
describe the transmission networks of treatment-naive
individuals with INSTI resistance mutations. We
included all 8825 individuals with genotypic resistance
testing in the cluster analysis. We based the analysis on the
partial polymerase ( pol) gene (2042 with protease/reverse
transcriptase, and INSTI genotypes, 6656 with only
protease/reverse transcriptase sequences, and 127 with
only INSTI sequences) using the first available sequence
per patient in the 2010–2016 study period. We aligned
sequences to HBX2 using multiple sequence comparison
by log expectation (MUSCLE); and edited sequences
manually for gapped positions [23]. We identified pairs of
sequences whose pairwise genetic distance was 0.015 or
less expected substitutions per site divergent based on the
Tamura–Nei 93 substitution model implemented in
HIV-TRACE as putative linkage between individuals
[24]. These linkages were constructed into clusters
composed of at least two linked individuals. We counted
any matching resolutions in nucleotide ambiguities as a
perfect match.
Phylogenetic analysis
We then performed a phylogenetic analysis to identify
clades defined by INSTI resistance mutations. For this
analysis, we used the first INSTI sequence available
during the 2010–2016 study periods from the 2784
individuals with INSTI resistance testing. Sequences were
aligned as above using MUSCLE and a maximum-
likelihood tree was constructed in FastTree v.2.1.4 with
the general time reversible model of nucleotide substitu-
tion [25,26]. The purpose of this analysis was to evaluate
for any INSTI resistance mutations circulating in clades at
larger genetic thresholds than would be identified in
the HIV-TRACE analysis. Statistical support of clades
was assessed with local support values [Shimodaira–
Hasegawa-like (SH-like) test] in FastTree.
Statistical analysis
We used the x2 test to compare the distributions of
categorical variables and the Kruskal–Wallis test for
continuous variables. We calculated the prevalence of
INSTI resistance mutations over the study period and by
year for those whose first genotype was sent 3 or less
months after diagnosis and for those whose first genotype
was sent more than 3 months after diagnosis. We
calculated binomial exact 95% confidence interval (CI)
for prevalence estimates. We performed a sensitivity
analysis and calculated the prevalence of INSTI resistance
mutations using alternative cutoffs of 1 month and
6 months to define the treatment-naı̈ve population. We
used logistic regression to determine trends in the
prevalence of INSTI resistance mutations over the study
period. Statistical significance was defined at the P value
less than 0.05 levels. We used STATA 14.2 for all analyses
(College Station, Texas, USA).
Results
Between 2010 and 2016, 2784 individuals contributed
3162 INSTI sequences [2289 (72%) by GenoSure PRIme
including protease/reverse transcriptase and INSTI
sequencing and 873 (28%) by GenoSure Integrase]. Of
the 2784 individuals with INSTI testing, 2470 (89%)
contributed one sequence and 314 (11%) contributed
more than one sequence (range 2–6).
Prevalence of integrase strand transfer inhibitor
resistance mutations among those with integrase
strand transfer inhibitor resistance testing within
3 months of diagnosis
Both patients who had first resistance testing 3 or less
months and more than 3 months after diagnosis
experienced an increase in INSTI resistance testing
overtime (P for trend< 0.001 for both groups; Table 1).
Compared to patients who had first resistance testing
more than 3 months after diagnosis, patients with testing
3 or less months after diagnosis were less likely to have an
INSTI sequence from 2010 to 2013; were younger; and,
more likely to be men, white or Hispanic, and identify as
men who have sex with men. Those with first resistance
testing 3 or less months after diagnosis had a greater viral
load and CD4þ cell count, and a shorter duration to
first genotype.
About 840 of 2784 (30%) individuals provided their first
sample for INSTI resistance testing 3 or less months after
diagnosis. In total 20 (2.4%, 95% CI: 1.5, 3.6%) of these
individuals had INSTI mutations, 18 (2.1%, 95% CI: 1.3,
3.4%) with only a minor mutation and two (0.2%, 95%
CI: 0.02, 0.9%) with a major mutation (Table 2). Both
individuals with major INSTI mutations had concomi-
tant reverse transcriptase resistance mutations.
The median age of the 20 individuals with INSTI
mutations was 27.5 (interquartile range; IQR 24–41). In
total 80% were men, 80% identified as black, and the most
common transmission risk was sex with another men.
All had subtype B virus. Median HIV viral load was
29 800 copies/ml (range: 600–6 856 570 copies/ml)
and median CD4þ cell count was 666 (range: 5–
1148 cells/ml). Median time from HIV diagnosis to first
genotype was 32 days (range: 4–74 days). In total 11
(55%) had a T97A/T mutation, 6 (30%) had a L74M
mutation, and 1 (5%) had an E138K mutation. Two
patients had major mutations: one with an S147G major
mutation and a T66A minor mutation (Patient 3) and one
with an N155H major mutation without minor
mutations (Patient 20). The most common reverse
transcriptase mutations were K103N (25%) followed by
G190A (5%), M184V (5%), and D67N (5%). There were
no major protease mutations. Patient 20 was identified
through the acute infection program of the North
Carolina Division of Public Health.
Sensitivity analysis of the definition of treatment-
naive individuals
Using a definition of treatment-naive individuals as those
with a genotype 1 month or less after HIV diagnosis, the
prevalence of any INSTI mutation was 10/520 or 1.9%
(95% CI: 0.9, 3.5%). One patient, patient 20 who was
identified with acute infection, had a major mutation
(0.2%, 95% CI: 0.005, 1.1%). Using a cutoff of 6 months
or less, the prevalence of any INSTI mutation was
22/908, or 2.4% (95% CI: 1.5, 3.6%). Three had a major
mutation (0.3%, 95% CI: 0.07, 1.0%). The additional
patient captured by increasing the cutoff to 6 months had
an N155H mutation with seven reverse transcriptase
mutations: M41L, D67N, V75M, M184V, L210W,
T215Y, K103N, and E138Q.
Prevalence of integrase strand transfer inhibitor
mutations among those with integrase strand
transfer inhibitor resistance testing 3 or more
months after diagnosis
Of the 1944 individuals who provided their first sample
for INSTI genotypic resistance testing more than
3 months after diagnosis, 187 (9.6%, 95% CI: 8.3,
11.0%) had INSTI mutations. Of these 187 individuals,
50 (27%) had only minor mutations, 128 (68%) had one
major mutation (with or without minor mutations), and
9 (5%) had two major mutations (with or without minor
mutations). Overall, the prevalence of any major
mutation was 137/1944 or 7.0% (95% CI: 5.9, 8.3%).
The prevalence of any and major INSTI resistance
decreased overtime. In 2010, 2/6 (33%, 95% CI: 4.3,
78%) had any resistance mutation, whereas in 2016
54/720 had any resistance mutation (7.5%, 95% CI: 5.7,
9.7%; P for trend<0.001; Fig. 1a). One of six (17%, 95%
CI: 0.4, 64%) patients in 2010 and 36/720 (5.0%, 95% CI:
3.5, 6.8%) in 2016 had major mutations (P for trend
<0.001; Fig. 1b).
Table 3 describes the sociodemographic and clinical
characteristics of those with no, minor, and major
mutations detected more than 3 months after diagnosis.
Few patients had two major mutations. Of the 10 patients
with two major INSTI mutations, three had S147G,
Q148R, and E138K mutations; two had S147 and
N155H mutations; and one each had E138EK, S147GS,
Q148QR; G140GS, Y143CHRY, Q148HQ; G140S,
Q148H, N115H; L74M, T97A, Y143C, S147G; and,
T97AT, G149GS, Q148QE, N115HN mutations.
Cluster analysis
Of the 8825 individuals who contributed sequences
between 2010 and 2016, 2899 (33%) comprised 774
clusters. In total 12 of the 20 individuals with INSTI
mutations in sequences collected within 3 or less months
of diagnosis were members of 10 distinct clusters with
median size three (IQR 2–8) and median node degree of
one (IQR 1–2.5; Fig. 2). In total 41% (55/93) of cluster
members had INSTI resistance testing. We observed two
clusters involving at least two INSTI mutations (clusters
270 and 222). In cluster 270, the pretreatment patient had
a T97A mutation and the treatment-experienced cluster
member had an R263KR mutation. In cluster 222, all
three members had L74M and K103N mutations. We
identified only one patient with pretreatment major
INSTI resistance in a cluster. Patient 3 with an S147G
major mutation was part of a cluster 1319; he and the
Table 1. Sociodemographic and clinical characteristics of HIV-positive individuals by timing of first integrase strand transfer inhibitor resistance
testing after HIV diagnosis, North Carolina, 2010–2016.
Individuals with first genotype
3 or less months after diagnosis
(n¼840)
Individuals with first genotype




2010 0 6 (<1)
2011 3 (<1) 50 (3)
2012 7 (<1) 76 (4)
2013 13 (1) 80 (4)
2014 135 (16) 340 (17)
2015 355 (42) 672 (34)
2016 327 (39) 720 (37)
Age, median (IQR) 30 (24–44) 43 (32–50) <0.001
Sex <0.001
Male 685 (82) 1378 (71)
Female 155 (18) 566 (29)
Race/ethnicity <0.001
Black 537 (64) 1452 (74)
White 190 (23) 337 (17)
Hispanic/Latino 85 (10) 87 (4)
Native American 8 (<1) 2 (<1)
Asian, Pacific Islander 6 (<1) 8 (<1)
Multiracial 14 (2) 57 (3)
Transmission risk
MSM (includes MSM/IDU) 522 (62) 910 (47) <0.001
IDU 16 (2) 129 (6)
Heterosexual 104 (12) 305 (16)
Other 198 (23) 600 (31)
Clinical characteristics
Subtype B 820 (98) 1908 (98) 0.361
HIV viral load (copies/ml), median (IQR) 43081 (14970–115538) [n¼574] 21981 (3000–79700) [n¼1278] <0.001
CD4þ cell count (cells/ml), median (IQR) 392 (216–575) [n¼574] 283 (113–488) [n¼1084] <0.001
Time to first sequence, days, median (IQR) 24 (12–41) 3639 (1885–5819) <0.001
Data are presented as n (%) unless otherwise specified. Numbers may not add to total because of missing data. HET, heterosexual; IDU, intravenous
drug use; INSTI, integrase strand transfer inhibitor; IQR, interquartile range; MSM, men who have sex with men.
treatment-experienced cluster member shared a G190A
mutation, but the cluster member did not have INSTI
genotypic resistance testing. Patient 20, the patient with
acute infection and an N155H major mutation, was not a
member of a molecular cluster.
Phylogenetic analysis
We identified nine clades with at least two sequences with
identical INSTI resistance mutations. Three clades
included pretreatment patients with INSTI mutations
in clusters 211, 222, and 270. Cluster 270 had a patient
with a pretreatment T97A mutation and a treatment-
experienced patient with an R263K mutation; phylo-
genetic analysis included an additional treatment-
experienced patient with T97A and F121Y mutations
(SH-like test¼ 0.96). In cluster 211, a cluster member
whose first sequence in the study period did not contain
an INSTI region, had a subsequent, but initial INSTI
sequence with a T97A mutation on phylogenetic analysis
(SH-like test¼ 1.0); this cluster also included three
sequences without INSTI mutations. Cluster 222
included no additional sequences or INSTI mutations
(SH-like test¼ 0.96). The six additional clades included
treatment-experienced individuals interspersed with
Table 2. Sociodemographic, clinical, and transmission cluster characteristics of individuals with integrase strand transfer inhibitor mutations
captured within 3 months of HIV diagnosis, North Carolina, 2010–2016.
Cluster
characteristics













1 2012 24 Male Black MSM ND ND 34 L74M None
2 2014 22 Male Black MSM 600 387 24 T97A None 270, 4 1
3 2015 45 Male Black HET 141 910 666 42 T66A, S147G G190A 1319, 2 1
4 2015 40 Male Black HET 6450 486 30 T97AT K103N 366, 14 4
5 2015 22 Male Black MSM 54 635 702 12 T97AT None 1358, 2 1
6 2015 42 Male White NIR 6 856 570 5 35 E138K None
7 2015 20 Male Black NIR 5410 805 23 L74M None 1299, 2 1
8 2015 32 Male Black MSM 288 872 383 34 T97A None 151, 8 1
9 2015 37 Male Hispanic MSM 11 676 775 54 T97A None
10 2015 26 Male Black MSM 46 326 155 23 T97AT None 1452, 2 1
11 2015 24 Male Hispanic MSM 847 760 74 T97AT None
12 2015 24 Male Black MSM 324 720 656 53 T97A K103N 211, 8 3
13 2015 19 Male Black MSM 15 200 836 13 T97A None 22, 48 11
14 2015 52 Female Black HET 23 400 964 39 L74M K103N 222, 3 2
15 2016 32 Female Black NRR 46 630 572 15 L74M K103N 222, 3 1
16 2016 29 Male Black MSM 29 800 538 68 L74LM None
17 2016 24 Female White HET 1450 1148 14 T97A None
18 2016 65 Male Black NRR 224 380 13 59 T97A None
19 2016 42 Female Black NRR 8828 732 4 L74M K103N 222, 3 1
20 2016 25 Male Black MSM 30 554 760 20 N155H D67N, M184V
HET, heterosexual; ID, identification; INSTI, integrase strand transfer inhibitor; MSM, men who have sex with men; ND, not done; NIR, adult with





























2010 2011 2012 2013 2014 2015 2016
Year
North Carolina, 2010−2016
Proportion of treatment−experienced individuals





























2010 2011 2012 2013 2014 2015 2016
Year
North Carolina, 2010−2016
Proportion of treatment−experienced individuals
with major INSTI resistance
(a) (b)
Fig. 1. (a) Prevalence of any INSTI resistance among treatment-experienced patients in North Carolina, 2010–2016.
(b) Prevalence of major INSTI resistance among treatment-experienced patients in North Carolina, 2010–2016. Error bars





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































individuals without INSTI mutations. The full phyloge-
netic tree is available as Supplementary Figure 1, http://
links.lww.com/QAD/B142.
Discussion
We found a low prevalence (0.2%) of major INSTI
resistance among patients with genotypes collected
within 3 months of an HIV diagnosis. To our knowledge,
this is the largest North American sample of individuals
with INSTI resistance testing to date. This low prevalence
of transmitted major INSTI mutations is consistent with
prior reports from Europe [6–10] and small sample of
patients with primary infection in Seattle, Washington,
USA [12]. A sensitivity analysis of alternate cutoffs to
define the treatment-naive population yielded similarly
low prevalence estimates.
Two patients had pretreatment major INSTI mutations.
One individual had an S147G major mutation, a
nonpolymorphic mutation associated with elvitegravir
resistance, as well as a T66A minor mutation that has also
been associated with elvitegravir resistance in combina-
tion with other INSTI mutations [27]. Neither of these
mutations appear to affect susceptibility to dolutegravir or
raltegravir. A second patient had an N155H mutation and
was diagnosed during acute infection. Viruses with an
N155H mutation show high-level resistance to raltegravir
and elvitegravir and low-level resistance to dolutegravir
[28,29]. This patient also had an M184V mutation as well
as D67N, a thymidine analogue mutation. This particular
thymidine analogue mutation has been described in
treatment-naive patients as viruses with D67N retain
replicative efficiency and can, thus, be transmitted
[30,31]. Transmitted M184V mutations appear to occur
in settings where the viral load of the population of
patients who are failing treatment is high because of the
lower fitness of viruses with this mutation [3]. Only the
patient with the S147G major mutation was part of a
transmission cluster; this patient and the cluster member
shared a G190A mutation. The cluster member did not
have INSTI genotypic resistance testing and we cannot
know if they also shared INSTI mutations.
Minor INSTI mutations in the treatment-naive popula-
tion concentrated among young, black men who have sex
with men. The most common minor mutations among
treatment-naive patients were T97A and L74M, natural
polymorphisms that have been found in individuals
without prior INSTI exposure and prior to the
widespread use of INSTIs [32–34]. We also observed
clustering of three women with both pretreatment L74M
and K103N mutations (cluster 222). Although prior
studies have documented clustering of individuals with
K103N mutations [3,35,36], likely because of preserved




























































































































































































































































































































































mutation, none have documented similar clustering of
individuals with L74M mutations. As sexual transmission
of HIV between women is rare [37], it is likely that
additional (men) members of the transmission cluster are
missing in our data (i.e. genotyping was performed before
2010 or performed elsewhere; the individual is not linked
to care; or the individual remains undiagnosed).
Phylogenetic analysis revealed three clades that included
five patients with pretreatment INSTI resistance who
were also part of clusters identified by molecular cluster
analysis. Only cluster 222 represented potentially
clustered transmission of minor INSTI mutations
(L74M). Other clades and clusters with sequences
with identical INSTI mutations were interspersed with
sequences with no or other INSTI mutations or with
sequences that frequently contained the same reverse
transcriptase mutations. For example, in cluster 211, most
individuals (75%) had K103N mutations, suggesting
clustered transmission of K103N. Phylogenetic analysis
showed that this clade included only two individuals with
T97A mutations; a pretreatment patient and a cluster
member who only had an initial protease/reverse
transcriptase sequence in the molecular cluster analysis
and a subsequent, initial INSTI sequence more than
3 months after diagnosis.
The prevalence of any and major INSTI mutation among
those with resistance testing more than 3 months after
diagnosis was 9.6 and 7.0%, respectively. The latter
estimate is lower than the 15.6% prevalence of major
INSTI mutations in the United States between 2009 and
2012 [14], but we also observed a decrease in the
prevalence of any and major mutations overtime. There
are a few explanations for this decrease. First, there has
been an increase in the collection of INSTI genotypic
resistance testing overtime. If the actual number of
patients with INSTI mutations remained the same
overtime (the numerator) but the number of individuals
on whom tests were sent increased overtime (the
Fig. 2. Molecular transmission clusters including individuals with pretreatment INSTI resistance mutations in North Carolina,
2010–2016. INSTI, integrase strand transfer inhibitor.
denominator), the prevalence would be lower. Second, if
the denominator became enriched with treatment-naive
individuals or treatment-experienced patients without
INSTI exposure overtime, the prevalence of INSTI
resistance would also appear lower. The use of GenoSure
PRIme resistance testing for protease/reverse transcrip-
tase and INSTI mutations, particularly in pretreatment
patients, may contribute to this explanation. Finally, the
decrease may reflect the effectiveness of HIV treatment in
patients treated with a regimen with an INSTI backbone,
particularly regimens containing dolutegravir [38,39],
which have increased over the same time period [40].
The study has several limitations. First, without
information on treatment history, we have likely
misclassified some treatment-naive individuals as treat-
ment experienced, particularly newly-diagnosed indi-
viduals who present to care or start treatment more than
3 months after diagnosis. Our sensitivity analysis,
however, yielded similar prevalences to the primary
analysis. Second, we restricted our cluster and phyloge-
netic analyses to individuals who provided at least
1 sequence for genotypic resistance testing between 2010
and 2016 from a single laboratory group. Thus, we are
missing clusters containing individuals with sequences
sent elsewhere for genotypic resistance testing, individuals
with genotypes collected outside the study period, and
individuals without genotype testing because of lack of
care engagement. Finally, there was significant missing-
ness in viral load and CD4þ data which may limit the
validity of comparisons based on these data.
In a large sample of HIV-positive patients in North
Carolina, we found the prevalence of transmitted major
INSTI resistance to be very low. Additionally, pretreat-
ment INSTI resistance is largely because of minor
mutations that are natural polymorphisms that are
unlikely to impact treatment outcome. These poly-
morphisms do not appear to indicate clustered HIV
transmission in this population. Nonetheless, INSTI
mutation surveillance remains important in the setting of
increasing use of INSTIs in the United States and
worldwide.
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